IRIS
ELENA, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.145
EU - Europa 858
AS - Asia 538
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
SA - Sud America 1
Totale 2.551
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.133
CN - Cina 527
IE - Irlanda 384
FI - Finlandia 121
UA - Ucraina 90
DE - Germania 79
IT - Italia 79
SE - Svezia 36
GB - Regno Unito 24
FR - Francia 17
BE - Belgio 16
CA - Canada 12
IN - India 5
AU - Australia 4
RU - Federazione Russa 4
EU - Europa 3
PL - Polonia 3
JP - Giappone 2
NL - Olanda 2
AT - Austria 1
BR - Brasile 1
EG - Egitto 1
GR - Grecia 1
HK - Hong Kong 1
LA - Repubblica Popolare Democratica del Laos 1
MU - Mauritius 1
RO - Romania 1
SG - Singapore 1
TR - Turchia 1
Totale 2.551
Salva come PNG Salva come JPEG
Città #
Dublin 384
Chandler 240
Nanjing 163
Jacksonville 144
Ashburn 104
Nanchang 67
Ann Arbor 63
Princeton 59
Lawrence 57
Medford 55
Beijing 53
Wilmington 51
Changsha 44
Helsinki 41
Hebei 38
Jiaxing 37
Shenyang 35
New York 28
Pavia 28
Hangzhou 20
Shanghai 18
Boardman 16
Brussels 16
Tianjin 14
Norwalk 12
Woodbridge 12
Toronto 11
Milan 10
Seattle 8
Jinan 7
Fairfield 5
Falls Church 5
Houston 5
Los Angeles 5
Verona 5
Washington 5
Kunming 4
Ningbo 4
Pune 4
Florence 3
Guangzhou 3
Redwood City 3
San Francisco 3
Taizhou 3
Tappahannock 3
Canberra 2
Fuzhou 2
Monza 2
Naples 2
Paris 2
Sesto San Giovanni 2
Zhengzhou 2
Andover 1
Athens 1
Auburn Hills 1
Berlin 1
Bolgare 1
Cairo 1
Central 1
Changchun 1
Como 1
Dearborn 1
Haikou 1
Hefei 1
Herne 1
Huzhou 1
Jinhua 1
Leawood 1
Mainz 1
Mariano Comense 1
Melbourne 1
Noale 1
Orange 1
Piediluco 1
San Giuliano 1
Sassari 1
Singapore 1
Stoney Creek 1
São Paulo 1
Tesero 1
Tokyo 1
Vanzaghello 1
Vientiane 1
Volgograd 1
Totale 1.941
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 88
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 75
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 75
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 75
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 70
Blast phase of essential thrombocythemia: A single center study. 69
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 69
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 65
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 63
Clinical significance of somatic mutation in unexplained blood cytopenia 59
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 58
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 57
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 56
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 55
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 55
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 55
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 55
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia 55
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 54
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 52
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 51
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 49
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 49
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 48
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms 48
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 48
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 45
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 45
Mutational status of myeloproliferative neoplasms. 44
Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis 44
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 44
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 43
‘Real-life’ study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis 43
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 43
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions 43
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis 42
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 41
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia 41
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 40
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 40
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications 39
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 38
Somatic mutations of calreticulin in myeloproliferative neoplasms 38
Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN 37
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 34
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 34
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 33
Incidence and Prognosis of Clonal Hematopoiesis in patients with Chronic Idiopathic Neutropenia 30
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem? 29
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 29
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 27
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. 27
Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry 26
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. 23
Validation of cytogenetic-based risk stratification in primary myelofibrosis. 22
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. 22
Relationship between clone metrics and clinical outcome in clonal cytopenia 20
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series 17
Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications 16
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes 15
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry 6
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 4
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis 2
Totale 2.719
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.196
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 0 3 9
2019/2020588 186 246 2 17 3 20 5 20 15 43 30 1
2020/2021227 26 19 4 21 2 18 12 40 21 32 21 11
2021/2022294 5 3 3 6 6 7 4 17 13 21 40 169
2022/2023858 79 62 5 45 81 64 0 38 434 7 30 13
2023/2024328 53 61 21 23 27 102 2 30 3 5 1 0
Totale 2.719